TrumpRx Faces Reality Check as Novo Nordisk Advances Obesity Drug, Alzheimer’s Therapies Re-evaluated

Recent developments in the pharmaceutical landscape highlight a tempered outlook for the TrumpRx prescription drug platform, advancements in obesity treatment and ongoing scrutiny of Alzheimer’s therapies. These shifts come as the industry navigates evolving pricing pressures and regulatory challenges.

TrumpRx: A Limited Tool, Not a Systemic Fix

Chris Klomp, Director of Medicare at the Centers for Medicare and Medicaid Services (CMS), offered a more restrained assessment of TrumpRx than President Trump’s initial characterization as “transformative.” Klomp framed the platform as a limited, cash-pay option rather than a comprehensive solution to high drug prices. STAT News reported on these comments during the STAT Breakthrough Summit East.

Novo Nordisk’s Wegovy Receives FDA Approval for Higher Dose

Novo Nordisk secured FDA approval for a higher-dose version of its injectable obesity drug, Wegovy. This approval provides a new catalyst for the company as it aims to regain market share in the competitive weight-loss market. Stat News details this development, positioning it as a key move for Novo Nordisk.

GLP-1 Pricing Agreements with Novo Nordisk and Eli Lilly

The Trump administration has reached agreements with Eli Lilly and Novo Nordisk to offer Most Favored Nation (MFN) prices on GLP-1 therapies, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). These manufacturers have also agreed to cap prices for insulin and other commonly prescribed diabetes medications. AMCP reports that the MFN price for GLP-1s available on the TrumpRx platform will be an average of $350 per month for vials, a 30% discount from current direct-to-consumer prices.

Alzheimer’s Therapies Under Review in the U.K.

U.K. Health officials have reopened a review of Eli Lilly’s Kisunla and Eisai and Biogen’s Leqembi, after initially determining they did not offer sufficient therapeutic value for their cost. This re-evaluation underscores the ongoing debate surrounding the pricing and efficacy of new Alzheimer’s treatments.

Other Pharmaceutical News

• Novartis is acquiring an experimental breast cancer drug from Synnovation Therapeutics for $2 billion upfront.
• Rhythm Pharmaceuticals received expanded FDA approval for Imcivree to treat acquired hypothalamic obesity, a rare condition causing accelerated weight gain.

Looking Ahead

The pharmaceutical industry continues to evolve, with pricing pressures, regulatory changes, and ongoing research shaping the landscape. The success of TrumpRx remains to be seen, while advancements in obesity and rare disease treatments offer hope for patients. Continued monitoring of Alzheimer’s therapy evaluations will be crucial as new treatments emerge.